1 December 2016

Growing, Hosting and Moving is great craic - but the funds you tirelessly raise is put to serious use. They enable groundbreaking men's health medical programmes in ireland and around the world.

The Work You Fund - Prostate Cancer Research in Ireland
iPROSPECT was established in 2014 with more than €745,000 of Movember Foundation funding, delivered through the Irish Cancer Society. It brings together a multidisciplinary team with the necessary clinical and scientific expertise to understand the challenges of prostate cancer and to take a fresh, innovative approach to transforming our knowledge of this disease.

iPROSPECT consists of connected and supported projects, all of which are integrated to bring about a transformation from current practice to a more individual and personalised treatment of patients with metastatic prostate cancer in order to improve patient outcomes. (Metastatic cancer is one that has spread from its location or origin to other parts of the body - usually into a patient's bones).

The iPROSPECT team is led by three principal specialist, one of whom is consultant medical oncologist, Prof Ray McDermott. Prof Ray is also a long-time Mo Bro who has so far raised €14,630 in 2016 alone!

According to Prof Ray:

"Prostate cancer is the second most common cancer in men worldwide. The Movember Foundation is working to halve the number of deaths from prostate cancer by 2030, and I want to help them get there. I am an Irish Medical Oncologist and many of the men I treat have advanced prostate cancer. Movember is helping us to get better treatments and greater options for these men. Help us to help these men live longer and live better."

Prof Ray and daughter

The team are all members of the National Prostate Cancer Research Consortium (NPCRC), established in 2011 to bring together like-minded scientists, clinicians, epidemiologists, health economists, statisticians, research nurses and allied healthcare professional from the academic research institutes of Ireland's leading universities, in addition to a range of well-established cancer focussed organisations.